Incorporating Narrative Into the Treatment of Youth With Anorexia Nervosa
NCT06849830
Recruiting
The goal of this clinical trial is to evaluate whether a narrative medicine (NM) curriculum can enhance self-expression, reflection, and resilience in adolescents and young adults with anorexia nervosa. The main questions it aims to answer are: * Does participation in an NM curriculum improve self-expression and reflection in individuals with anorexia nervosa? * Does engaging in creative writing and group discussion promote resilience and emotional processing in this population? Participants... Read More
Gender:
ALL
Ages:
Between 16 years and 25 years
Trial Updated:
03/31/2025
Locations: UCSF Nancy Friend Pritzker Psychiatry Building, San Francisco, California
Conditions: Anorexia Nervosa
Register for Updates
A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma
NCT06891560
Recruiting
The purpose of this study is to find out whether enfortumab vedotin is an effective and safe treatment for people with adenoid cystic carcinoma (ACC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Adenoid Cystic Carcinoma
Register for Updates
Retrospective Analyses of TrakStar Database
NCT06917339
Recruiting
In this study, real-world data will be used to better understand the effects patient characteristics, symptoms and TMS protocol parameters have on clinical outcomes with NeuroStar TMS.
Gender:
ALL
Ages:
Between 5 years and 120 years
Trial Updated:
03/31/2025
Locations: Neuronetics, Malvern, Pennsylvania
Conditions: Depression, Obsessive-Compulsive Disorder, Anxiety Depression
Register for Updates
Mayo AVC Registry and Biobank
NCT03049254
Recruiting
Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest or death is the most tragic and dangerous. Diagnosis and screening of blood-relatives is very difficult as the disease process can be subtle, but sufficient enough, so that the first event is sudden death. The Mayo Clinic AVC Registry is a collaboration between Mayo Clinic, Rochester, USA and Papworth Hospital, Cambridg... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/31/2025
Locations: Mayo Clinic, Rochester, Minnesota +1 locations
Conditions: Arrhythmogenic Right Ventricular Cardiomyopathy, Cardiomyopathies, Heart Diseases, Cardiovascular Diseases, Sudden Cardiac Arrest, Sudden Cardiac Death, Arrhythmogenic Right Ventricular Dysplasia, Arrhythmogenic Ventricular Cardiomyopathy, Familial Dilated Cardiomyopathy, Cardiovascular Abnormalities, Sarcoidosis, Cardiac Arrhythmia, Cardiac Sarcoidosis, Myocarditis, Inflammatory Cardiomyopathy, Ventricular Tachycardia, Right Ventricular Outflow Tract Ventricular Tachycardia
Register for Updates
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
NCT04224493
Recruiting
The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to esta... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Southern Cancer Center, Mobile, Alabama +191 locations
Conditions: Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Register for Updates
Improving Care After Inherited Cancer Testing
NCT04763915
Recruiting
The IMPACT Study seeks to refine and evaluate the effectiveness of interventions on improving guideline-adherent cancer risk management (CRM) and family communication (FC) of genetic test results for individuals with a documented pathogenic/likely pathogenic (P/LP) variant, and FC of family cancer history for individuals with a variant of uncertain significance (VUS) in an inherited cancer gene.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Conditions: Inherited Cancer Syndrome, Prostate Cancer, Colorectal Cancer, Endometrial Cancer, Breast Cancer
Register for Updates
Developing and Testing an Online Pathway From Screening to Treatment for Depression in Oncology: iPath*D (Aim 2)
NCT05302375
Recruiting
The purpose of this study is to determine the extent to which an online pathway to depression treatment (iPath\*D) is acceptable and usable to patients receiving cancer treatment who report symptoms of depression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Dartmouth Cancer Center St. Johnsbury, Saint Johnsbury, Vermont
Conditions: Cancer, Depression
Register for Updates
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
NCT05475925
Recruiting
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Dren Investigational Site, Birmingham, Alabama +33 locations
Conditions: LGLL - Large Granular Lymphocytic Leukemia, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Aggressive NK Cell Leukemia, Systemic EBV1 T-cell Lymphoma, if CD8 Positive, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Extranodal NK/T Cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker), Cutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)
Register for Updates
Evaluate Pharmacokinetics and Safety of Slow Release DHEA
NCT05623059
Recruiting
This is a study to look at pharmacokinetic levels of different doses of slow release DHEA in subjects with asthma.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
03/31/2025
Locations: Riley Hospital for Children, Indianapolis, Indiana +1 locations
Conditions: Asthma, Genotype
Register for Updates
TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning
NCT05743842
Recruiting
To learn if using the TriNav Infusion System (TriNav catheter) for the injection of the surrogate/test dose during the planning part of the radioembolization procedure and your actual treatment with the radioactive microspheres match each other better than the standard catheter.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Liver Cancer
Register for Updates
AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia
NCT05848713
Recruiting
This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with community acquired pneumonia (CAP).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: University of Chicago, Chicago, Illinois +61 locations
Conditions: Community-acquired Pneumonia
Register for Updates
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
NCT05999240
Recruiting
This Phase 2 study examines the safety, tolerability, and preliminary efficacy of pimavanserin in individuals with Autism Spectrum Disorder. Male or female participants aged 16 to 40 years of age will be randomized to receive single doses of either placebo or pimavanserin in this randomized, placebo-controlled, cross-over designed study, followed by open label extension.
Gender:
ALL
Ages:
Between 16 years and 40 years
Trial Updated:
03/31/2025
Locations: Wakarusa Research Facility, Lawrence, Kansas +1 locations
Conditions: Autism Spectrum Disorder
Register for Updates